Table 3.
Spirometry, 6MWD, oxygen requirement, NYHA functional class, and scadding stage at time of PH diagnosis.
| Treated SAPH (n = 38) | Untreated SAPH (n = 20) | |
|---|---|---|
| FEV1 (L) | 1.2 ± 0.5 | 1.4 ± 0.6 |
| % Predicted FEV1 (%) | 45.7 ± 15.6 | 49.8 ± 17.9 |
| FVC (L) | 1.7 ± 0.6 | 2.0 ± 0.8 |
| % Predicted FVC (%) | 52.3 ± 13.6 | 54.6 ± 18.3 |
| FEV1/FVC > 0.7, n (%)* | 18 (47.3) | 15 (75.0) |
| Percent‐predicted DLCO | 26.7 ± 12.3 | 29.6 ± 11.8 |
| 6MWD (m) | 224.4 ± 89.0 | 267.7 ± 78.3 |
| NYHA functional class | ||
| II, n (%) | 0 (0) | 1 (5) |
| III, n (%) | 16 (42.1) | 13 (65) |
| IV, n (%) | 22 (57.9) | 6 (30) |
| Scadding stage | ||
| 0, n (%) | 0 (0) | 0 (0) |
| I, n (%) | 0 (0) | 0 (0) |
| II, n (%) | 0 (0) | 0 (0) |
| III, n (%) | 0 (0) | 0 (0) |
| IV, n (%) | 38 (100) | 20 (100) |
Abbreviations: 6MWD, 6‐minute walk distance; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, functional vital capacity; NYHA, New York Heart Association; PH, pulmonary hypertension; SAPH, sarcoidosis‐associated pulmonary hypertension.
*
p < 0.05.